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Abstract
Many biosensors that have been developed to sense environmental changes or chemicals 
rely on change of phenotype assays. These assays often require special equipment or 
addition of reagents to detect fluorescence and can be both time and cost intensive. Here,
a colorimetric in-vitro ligand–binding assay is proposed using β-galactosidase (β-gal, 
from the lacZ gene) in bacterially-expressed protein biosensors. The use of β-
galactosidase-based assays (based on ONPG hydrolysis) for ligand-binding biosensors 
presents the advantage that β-galactosidase and the related reagents/equipment necessary 
are cost-effective, easily reproducible, commercially available, and much faster than 
traditional assays. The work to be presented was started with an established biosensor 
that transduces a test hormone-binding activity (estrogen) into a growth-phenotype. To 
obtain a colorimetric signal for binding rather than a growth phenotype, the growth 
phenotype reporter gene (thymidylate synthase) was replaced in the biosensor expression 
vector with the β-galactosidase gene. To verify our vector activity, cells were grown with 
and without estrogen and colorimetric assays were carried out on cell lysates to determine 
β-gal activity. Originally, the vector containing β-galactosidase was expressed in 
BL21(DE3 T7g1) recA lacZ+ strain (BLR) but the chromosomal lacZ+ was contributing 
background noise to the assay. To eliminate this background signal, the strain ER2566 
(ΔlacZ::T7g1) was used for expression studies and three trials of β-gal assays implied 
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higher β-gal / lacZ+ activity for cells grown with ligand than cells grown without ligand,
suggesting the strain background was no longer contributing to noise. Next, cells were 
grown in the absence of the estrogen ligand and were lysed as estrogen was added to the 
lysate with the colorimetric assay reactant in-vitro while optimizing the dilution to allow 
for a longer assay so that the in-vitro additions of ligand would have adequate time to 
bind and potentially increase activity. Despite multiple attempts, no appreciable results 
were obtained during this step. A new experiment was devised which consisted of 
purifying the target protein of any proteases and cell debris through affinity 
chromatography involving binding to an amylose resin column. Estrogen ligand was then 
added to the purified protein and colorimetric assays were performed to test for increased 
β-gal activity. The in-vitro estrogen ligand additions to the purified protein showed no 
discernible changes in activity trends between the controls and samples tested. A 
hypothesis was formed that when cells took up the ligand in-vivo during growth, the 
ligand helped the ligand-binding domain fold properly during translation which produced 
the desired activity increase. However, it is believed that when the ligand was introduced 
in-vitro after lysis or purification, the ligand binding domain was improperly folded or 
the active site was buried which caused the suppression of changes in enzyme activity. A 
series of experiments were then carried out involving the in-vivo introduction of a
weakly-binding stabilizing molecule (an estrogen antagonist) that would bind and help 
the ligand-binding domain fold properly during translation with the hope of introducing 
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estrogen agonists in-vitro after lysis or purification that would theoretically compete for 
binding and cause an increase in enzyme activity. Several experimental variations had 
been utilized along with many trials, but in-vitro estrogen ligand additions with or 
without antagonist molecules introduced in-vivo failed to produce any changes in β-gal 
enzyme activity. An additional experiment that had been performed concurrently to those 
presented here involved a similar construct to the human estrogen receptor but the 
receptor was of the human thyroid (TRβ), which has intrinsically higher signal to noise. 
The addition of thyroid ligands taken up in-vivo showed an identical trend with the 
thyroid receptor biosensor to that of estrogen additions to the estrogen biosensor. 
Although increased activity was defined at this step in an analogous manner, the failed 
progress of the estrogen receptor biosensor led to conclusion that the thyroid biosensor 
would behave in a similar manner and yield inconclusive in-vitro findings. As such, in-
vitro ligand additions with the thyroid biosensor were never attempted due to the 
comparable nature of the hypothesized ligand-binding domain folding problem and due 
to the fact that there are no known thyroid antagonists that could potentially bind in-vivo 
only to get competitively displaced with the addition of binding thyroid agonists in-vitro.
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1Background and Introduction
The research presented in this work depends fundamentally on the introduction of an 
interfering protein (intein) into the DNA coding sequence for each of the bacterially 
expressed protein biosensors. Inteins are biological macromolecules that undergo self-
splicing reactions to fuse the ends of the intein together (the N-extein and C-extein,
respectively) while excising the middle portion. This unique reaction has a broad range of 
potential applications in the purification of proteins and as a functioning linker molecule 
in bacterial biosensors. The main amino acids that participate in the self-splicing reaction 
are the cysteine, serine, or threonine residues on the N-terminus and the histidine or
asparagine residues on the C-terminus. Through genetic manipulation, these residues can 
be mutated to effectively restrict intein activity at either of the intein-extein bonds to 
generate an intein with single-site cleavage potential. One of the mutations that had been 
developed was a C1A mutation at the start of the intein coding sequence which 
successfully froze the N-terminus from participating in the splicing reaction, but did not 
inhibit the C-terminus from undergoing cleavage [1, 2].
The enzyme thymidylate synthase (TS) has been used as a valuable tool to study the 
effects of genetic mutations on inteins. TS is a phenotype growth reporter that when 
actively expressed in TS-knockout bacterial strains allows the cells to grow in the 
absence of thymine. When fused to the N-terminus of the intein, TS has been shown to be 
2inactive, but TS activity has been restored when linked to the cleavable C-terminus. The 
exact reason for this difference in activity is unknown, but it has been speculated that 
upon cleavage, TS forms a dimer which renders it more active, thus, when linked to the 
C-terminus of the intein, TS can aid in mutant selection on thymineless media which can 
be quantified by analyzing the growth phenotype of cells [1].
Genetic mutations using TS as a growth and activity modulator have produced mutant 
inteins that are susceptible to both temperature and pH. When a maltose binding domain 
had been added to the frozen N-terminus of the intein, a purification platform had been 
developed which would allow the maltose binding protein to bind to the resin in an 
amylose affinity column and upon changing the reaction temperature or pH of the buffer, 
the cleavage of the intein could be influenced to yield a relatively pure product protein.
Another interesting development had been discovered when the ligand-binding domain of 
a human estrogen nuclear hormone receptor had been linked to the central domain of a 
genetically modified intein to yield a three-part protein consisting of maltose binding 
protein (MBP), an intein with an estrogen receptor (ERβ), and TS. The intein and maltose 
binding protein increased the solubility and stability of the estrogen receptor, but cells 
were still unable to grow with the new chimeric fusion protein until a genetic mutation 
was introduced to generate mutants that demonstrated an increase of growth in the 
presence of an estrogen ligand on thymine-less media in the TS-deficient E. coli strain 
3D1210ΔthyA. Effectively, a bacterial biosensor was created that showed hormone 
dependent activity which was expressed via changes in phenotype growth in selective 
media [1-5]. 
Nuclear hormone receptors are an important part of the endocrine system and their 
involvement has been linked to a variety of diseases which makes them an important
point of interest as drug targets. As such, it was desired to extrapolate the results of the 
estrogen receptor (ERβ) to include another receptor, namely the human thyroid receptor 
(TRβ). When the nuclear hormone receptor was successfully swapped out, the cells 
containing the new TRβ mutants could only grow in thymine-less media in the presence 
of the natural thyroid hormone (T3) but had no differences in effect when an estrogen 
was added, which demonstrated ligand-receptor specificity. When the intein was removed 
from the sequence altogether, growth was significantly reduced which showed that the 
intein played a vital role in the function of the biosensor.  It was necessary to test each 
biosensor with a variety of compounds to demonstrate their functionality as tools for drug 
discovery. An assortment of agonists was tested for the TRβ receptor along with a variety 
of agonists and antagonists tested with the ERβ receptor. The results illustrated that only 
estrogen agonists/antagonists had any effect on the ERβ biosensor with an analogous 
effect correlated to the TRβ biosensor using thyroid agonists. The general outcome was 
that compounds with higher binding affinities to the ligand-binding domain caused 
4greater changes in growth [1, 3-5]. Thus, the format of these assays could be converted to 
a 96-well plate format to yield a high throughput assay which could essentially detect 
potency of each small molecule ligand through the use of a plate reader. The successes of 
these experiments generated a novel tool that could be used for early drug screening as 
well as for analyzing environmental toxicity of molecular entities [3-5]. 
Though this was a significant step towards finding the solution to an important problem, 
there are some limitations. The main drawback for these assays is the dependence on
time. E. coli cells need to be grown overnight before being converted to a 96-well plate 
and then incubated for several more hours after transfer. The work presented here aims to 
improve this constraint through the use of a different target protein other than 
thymidylate synthase that could have the same effect through a much faster route. It was 
also desirable to extrapolate the results from in-vivo ligand additions to in-vitro ligand 
additions so that the protein moiety could be extracted and purified from the cells in 
adequate quantities to additionally cut back on time constraints for reproducible high 
throughput results.
5Methodology
The protein that was selected to expand upon the previous experiments is an enzyme 
known as β-galactosidase (β-gal) which has several applications in microbiology as a 
reporter protein. β-gal is 1,024 amino acids long and forms homologous tetramers. It is 
encoded by the LacZ gene and is recognized for the hydrolysis of β-galactosides into 
monosaccharide subunits. One of the more convenient substrates used for β-gal assays is 
ortho-nitrophenyl-β-galactoside (ONPG) for the reason that after hydrolysis, the ortho-
nitrophenol product turns yellow and the amount of hydrolyzed product can then be 
quantified with a standard spectrophotometer. 
                        
Figure 1: β-galactosidase reaction with ortho-nitrophenyl-β-galactoside
6Upon successful replacement of thymidylate synthase with β-galactosidase, the assay 
format could be converted from a multi-hour growth phenotype assay to a colorimetric 
assay that takes less than five minutes to obtain data.
The DNA coding for wild type β-galactosidase was obtained and isolated from a stored 
vector (pET-E11-I-βgal). The desired endonuclease restriction sites for proper cutting and 
removal of βgal were Xba1 and Bsrg1. The vector containing the thymidylate synthase
(pMIT::ERβ) contained both restriction sites, but the vector containing β-gal was missing 
the Xba1 site. Primers were designed to add an Xba1 site through a polymerase chain 
reaction (PCR) to successfully swap the target proteins. After DNA digestion and ligation 
of the vector, the desired protein sequence was obtained yielding maltose binding protein, 
an intein with an ERβ ligand binding domain, and β-galactosidase (referred to 
collectively as MIβ-gal::ERβ). The sequence was confirmed through the use of a whole-
cell PCR and a DNA agarose gel.
After successful confirmation of the desired protein sequence, the new MIβ-gal::ERβ 
vector was transfected into a BLR strain of E. coli. The cells were grown in liquid growth 
media (Luria-Bertani) overnight and then transferred to over-day cultures in the presence 
of an ERβ ligand (Estradiol). An identical experiment was performed in the same fashion 
simultaneously with dimethyl sulfoxide (DMSO) added instead of the estrogen ligand to 
serve as a negative control. Both groups were grown until an optical density of ~1.0 was 
7obtained at 600 nm. The cells were then re-suspended in assay buffer (Z-buffer) and the 
OD600 was measured of the re-suspended cells. It was necessary to extract the protein 
from the cells via lysing and centrifugation after which the protein dilution was optimized 
and found to be 1:10 in assay buffer to yield a reaction time of 3.5 minutes. The ONPG 
substrate mixture was added to the protein and the time of reaction was recorded 
precisely. After the reaction was sufficiently allowed to continue for the allotted time, the 
reaction was quenched with 1M Na2CO3 which raises the pH to 11 and ultimately
terminates the reaction. The resulting mixture was yellow in color and the optical density 
was subsequently recorded at 420 nm (OD420) and 550 nm (OD550). The activity of β-gal 
was then measured with Eq. (1) which quantified the activity in Miller Units.   
Miller Units = 
? ? ? ? (? ? ? ? ?−? .? ? ? ? ? ? ? )? ?? ? ∗ ? ? ?? ? ? ∗ ? ? ? ? ?                         (1)
The results for the initial experiment can be found in Table 1 below.
Table 1: In-vivo β-gal activity assay results for MIβ-gal::ERβ in presence and absence of 
estrogen ligand in BLR strain of E. coli.
Plasmid (Ligand, Strain) Activity (Miller Units)
MIβ-gal::ERβ (Estradiol, BLR) 1143.2
MIβ-gal::ERβ (DMSO, BLR) 984.662
8At first glance, the biosensor appeared to function as predicted with the addition of ligand 
causing an increase in β-gal activity while the addition of pure DMSO caused a lesser 
amount of activity. The experiment was repeated under identical conditions and the 
results of the replicate can be found tabulated in Table 2 below.
Table 2: In-vivo β-gal activity assay results (repeated) for MIβ-gal::ERβ in presence and 
absence of estrogen ligand in BLR strain of E. coli.
Plasmid (Ligand, Strain) Activity (Miller Units)
MIβ-gal::ERβ (Estradiol, 
BLR) 1198.62
MIβ-gal::ERβ (DMSO, BLR) 1461.65
Upon further investigation and data analysis, the calculated data from both trials was 
discovered to have a very low signal to noise ratio and the results of the assays were 
found to be inconclusive. It was then brought to attention that the BLR strain of E. coli
that was used contained endogenous chromosomal β-galactosidase which was interfering 
with the results of the β-gal assays and producing the noise. The entire MIβ-gal::ERβ
plasmid sequence was then transformed into a LacZ operon knockout strain of E. coli
known as ER2566 in an effort to minimize interference from β-galactosidase not 
originating from the plasmid sequence of interest. The preliminary in-vivo experiments
9and β-gal assays were then repeated in the ER2566 strain and a much stronger signal was 
obtained. The results were then repeated once in duplicate and the activity can be seen 
below in Table 3 and Table 4. 
Table 3: In-vivo β-gal activity assay results for MIβ-gal::ERβ in presence and absence of 
estrogen ligand in ER2566 strain of E. coli.
Plasmid (Ligand, Strain) Activity (Miller Units)
MIβ-gal::ERβ (Estradiol, ER2566) 3539.11
MIβ-gal::ERβ (DMSO, ER2566) 2281.26
MIT::ERβ (no β-gal, Estradiol, ER2566) 151.03
Table 4: In-vivo β-gal activity assay results (repeated in duplicate) for MIβ-gal::ERβ in 
presence and absence of estrogen ligand in ER2566 strain of E. coli.
Plasmid (Ligand, Strain) Activity (Miller Units)
MIβ-gal::ERβ (Estradiol, ER2566) 3539.07
MIβ-gal::ERβ (DMSO, ER2566) 2853.36
MIT::ERβ (no β-gal, Estradiol, ER2566) 136.05
(Duplicate)
MIβ-gal::ERβ (Estradiol, ER2566) 3715.06
MIβ-gal::ERβ (DMSO, ER2566) 2908.25
MIT::ERβ (no β-gal, Estradiol, ER2566) 142.86
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In Table 3 and Table 4, the original construct MIT::ERβ containing the original reporter 
protein thymidylate synthase was introduced to serve as a second negative control. Since 
neither the vector nor the strain contained β-gal, the activity signal was observed to be 
extremely low, as expected for this control. Additionally, the activity for the MIβ-
gal::ERβ constructs was on average ~900 Miller Units higher when estrogen ligand was 
introduced during over-day growth than when pure DMSO was added. The hypothesis
for the observed activity increase is that ligand-induced cleaving allows the target protein 
to oligomerize (β-gal potentially forms a tetramer, TS potentially forms a dimer) which 
renders the reporter protein more active. This is historically consistent with previous 
results and is in good agreement with the data presented here, but attempts to further 
prove this hypothesis were not explored any deeper in this work. 
Following the success of obtaining a greater β-gal activity signal for in-vivo ligand 
additions, a modified experiment was then devised very similar to the previous
experiment with the exception that the ligand was to be added post-translationally in-vitro
after the protein had already been expressed and the cells had already been lysed. The 
reaction time was also extended to 30 minutes to allow for sufficient ligand-receptor 
binding time after cell-lysis, but the data that was obtained had a very low signal to noise 
ratio and nothing conclusive was determined after repeated attempts. The raw β-gal 
activity data for these trials can be seen in Table 5 and Table 6.
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Table 5: In-vitro β-gal activity assay results for MIβ-gal::ERβ in the presence of estrogen 
ligands and DMSO added after cell-lysis in ER2566 strain of E. coli
Plasmid (Ligand, Strain) Activity (Miller Units)
MIβ-gal::ERβ (diethylstilbestrol, ER2566) 1627.74
MIβ-gal::ERβ (estradiol, ER2566) 1787.41
MIβ-gal::ERβ (bisphenol a, ER2566) 2255.21
MIβ-gal::ERβ (DMSO, ER2566) 1937.85
Table 6: In-vitro β-gal activity assay results (repeated) for MIβ-gal::ERβ in the presence 
estrogen ligands and DMSO added after cell-lysis in ER2566 strain of E. coli
Plasmid (Ligand, Strain) Activity (Miller Units)
MIβ-gal::ERβ (diethylstilbestrol, ER2566) 1700.62
MIβ-gal::ERβ (estradiol, ER2566) 1653.38
MIβ-gal::ERβ (bisphenol a, ER2566) 1747.08
MIβ-gal::ERβ (DMSO, ER2566) 1841.71
It was expected that the β-gal activity would show a positive correlation with the binding 
affinity of each estrogen ligand with the human estrogen β receptor, but no such trend 
could be deduced from the preceding data. Additionally, it was expected that the negative 
control (DMSO) would show the least amount of  β-gal activity analogous to the 
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preliminary in-vivo experiments, but this observation was not apparent for these in-vitro 
whole-lysate ligand addition experiments. It was hypothesized that some of the other 
cellular components such as proteases were interfering with or destroying the protein of 
interest before sufficient binding, cleavage, and activity could be quantified. Thus, it was 
necessary to purify the protein to rid it of these components in an effort to generate 
meaningful data.
In the next set of experiments, the cells were grown in the absence of ligand and were 
expressed at 37C. After lysis and centrifugation, the resulting protein was purified 
through an amylose column, ligand was introduced to the purified protein along with 
negative controls in separate experiments, and the resulting mixtures were incubated. 
Rather than measure enzyme activity at this step, the protein was run on an SDS-PAGE
protein gel with a molecular weight standard to quantify the components of the mixture. 
There was no difference in cleavage products between the control sample and the ligand 
sample which led to a hypothesis that the ligand-binding domain was improperly folding 
in the absence of its substrate and that the active site was getting buried rendering ligand 
additions post-translation as ineffective. Thus, adding ligands post-translationally either 
in the lysate or to purified protein gave inconclusive results.
Traditionally, the human TRβ receptor has given a much higher signal to noise ratio than 
the corresponding ERβ receptor. The TRβ version of the above protein was then designed 
13
and obtained in a very similar manner to that of the ERβ receptor through molecular 
cloning to give MIβ-gal::TRβ. MIT::TRβ was used as the vector backbone while MIβ-
gal::ERβ was used as the insert departure point to swap thymidylate synthase for β-gal in 
the backbone vector using the same restriction sites as before (Xba I and Bsrg I) to give 
the new MIβ-gal::TRβ clone. A colony PCR and digest check were performed and the 
new clones were found to contain the proper insert (β-gal). The clones were then 
transformed into the same LacZ knockout strain of E. coli (ER2566) and the initial ERβ 
experiments were performed on the new TRβ clones using the appropriate thyroid ligand 
that fit the new receptor. Here, triiodothyroacetic acid (triac) and triiodothyronine (T3) 
were chosen as the thyroid ligands of interest for the new human thyroid receptor β. The 
ligands were introduced separately during over-day cell growth along with negative 
controls of estradiol (estrogen ligand) and DMSO.  The cells were then centrifuged, 
lysed, and assayed using the same β-gal assay with the activity quantified in Miller Units. 
The activity results can be viewed in Table 7. 
Table 7: In-vivo β-gal activity assay results for MIβ-gal::TRβ in presence and absence of 
thyroid ligands T3 and triac with E2 (negative control) and DMSO (negative control) in 
ER2566 strain of E. coli.
Plasmid (Ligand, Strain) Activity (Miller Units)
MIβ-gal::TRβ (triac, ER2566) 4572.25
MIβ-gal::TRβ (T3, ER2566) 4430.69
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MIβ-gal::TRβ (estradiol (E2), ER2566) 2766.85
MIβ-gal::TRβ (DMSO, ER2566) 2550.53
As expected, a very good signal was obtained for the ligand samples and the difference in 
activity was much more significant for the TRβ receptor when comparing the negative 
controls with the ligand samples. The results were repeated again in duplicate to ensure 
that the data was meaningful. Table 8 and 9 show the repetition results of this 
experiment.
Table 8: In-vivo β-gal activity assay results (repeated) for MIβ-gal::TRβ in presence and 
absence of thyroid ligands T3 and triac and DMSO (negative control) in ER2566 strain of 
E. coli.
Plasmid (Ligand, Strain) Activity (Miller Units)
MIβ-gal::TRβ (triac, ER2566) 3482.0
MIβ-gal::TRβ (T3, ER2566) 4067.34
MIβ-gal::TRβ (DMSO, ER2566) 1748.48
Table 9: In-vivo β-gal activity assay results (duplicate) for MIβ-gal::TRβ in presence and 
absence of thyroid ligands T3 and triac and DMSO (negative control) in ER2566 strain of 
E. coli.
Plasmid (Ligand, Strain) Activity (Miller Units)
MIβ-gal::TRβ (triac, ER2566) 3221.53
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MIβ-gal::TRβ (T3, ER2566) 3838.26
MIβ-gal::TRβ (DMSO, ER2566) 1528.30
For the data obtained in Tables 8 and 9, the E2 (estradiol) negative control had been 
omitted for convenience and since ligand-receptor specificity had already been 
demonstrated historically in previous work, in the ERβ in-vivo trials, and in the first in-
vivo trial of this TRβ experiment. From Tables 8 and 9, it is also apparent that the overall 
trend is conserved and that both the ERβ and now the TRβ clones exhibit greater increase 
in β-gal activity with a β-gal assay when the cells are grown with the appropriate ligands. 
The ERβ clones, however, had failed at producing relevant data when adding ligands to 
either the lysate or the purified protein in-vitro and it was assumed that the TRβ clones 
would give similar results. Thus, since the ERβ clones had failed with the in-vitro
experiments at the same time that the TRβ clones were being made, the TRβ clones were 
not tested further. 
In order to study the human ERβ receptor in more depth, MIβ-gal::ERβ cells were grown 
and over-expressed with IPTG at 20 °C for 3 hours. Estradiol (ERβ ligand) was added 
during over-expression along with the IPTG in order to allow the ERβ ligand-binding 
domain to fold properly during protein translation. In addition, one sample received 
DMSO to serve as the negative control. Both the ligand and no ligand samples were then 
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lysyed and purified on an amylose column at pH 7.0 and pH 7.5. The fractions were then 
run on an SDS-PAGE protein gel to quantify expression and cleavage products. It was 
hypothesized that the samples that received ligand expression would show cleavage 
products consistent with historical data while the DMSO sample would show no cleavage 
products and the lanes would consist of mostly precursor protein. As can be seen below 
in Figure 2, each of the ligand and DMSO purification products showed identical 
cleavage products at this expression temperature and time.
Figure 2: SDS-PAGE protein gel of MIβ-gal::ERβ over-expressed with IPTG with and 
without estradiol for 3 h at 20°C and purified on amylose column
1    2     3     4    5   6   7     8   9   10   11    12  13  14  15
1.) Marker (kDa)
2.) Whole Lysate (+ estradiol)
3.) Clarified Lysate (+)
4.) Flow Through (+)
5.) Elute (+) pH 7.5
6.) Elute (+) pH 7.5 (+2 days at 4°C)
7.) Elute (+) pH 7.0
8.) Elute (+) pH 7.0 (+2 days at 4°C)
9.) Whole Lysate (- estradiol)
10.) Clarified Lysate (-)
11.) Flow Through (-)
12.) Elute (-) pH 7.5
13.) Elute (-) pH 7.5 (+2 days at 4°C)
14.) Elute (-) pH 7.0
15.) Elute (-) pH 7.0 (+2 days at 4°C) 
116
66
45
35
25
18
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The target protein MIβ-gal::ERβ is 204 kilo-Daltons (kDa) and can be seen in the whole 
lysates, clarified lysates, and elute fractions as the very top dark band above the 116 kDa 
marker in Figure 2. The reason it is not present in the flow through wells is because this 
is the point where the protein is bound to the amylose column before becoming displaced 
with maltose in lanes 5-8 and 12-15. In these wells, we see cleavage around 88 kDa in 
both ligand and DMSO samples at both measured values of pH. This cleavage 
corresponds to the molecular weight of M-I::ERβ fraction (88 kDa) with a cleaved and 
washed β-gal fragment (116 kDa). This is the expected result for the protein samples 
expressed with ligand, but for the DMSO samples, this was somewhat of an anomaly. 
The protein was expected to have an improperly folded ligand-binding domain in the 
absence of a stabilizing molecule such as a ligand, which should have produced no 
cleavage products. The result would have been nothing but precursor band at the top of 
the gel in lanes 12-15 in Figure 2 above, but this was not the case and premature cleavage 
occurred independent of ligand-receptor interaction. 
The same experiment above was repeated but with an expression temperature of 37°C 
and with an additional elution fraction taken at pH 6.5. The results can be seen in Figure 
3.
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Figure 3: SDS-PAGE protein gel of MIβ-gal::ERβ over-expressed with IPTG with and 
without estradiol for 3 h at 37°C and purified on amylose column
In Figure 3, the protein gel had ripped during handling, but the end result had agreed with 
the expected result considerably. The protein over-expressed in the presence of ligand 
had cleavage products around 88 kDa (lanes 5-7) while the protein expressed in DMSO 
had nothing but precursor (lanes 11-13). This result is very significant because it is the 
strongest evidence to support that ligand-receptor interactions cause both cleavage and an 
activity increase when the ligand is added during growth or over expression. The idea is 
that the ligand helps the ligand-binding domain fold properly during translation which 
ultimately is suspected to cause cleavage and renders the free β-gal fragment more active
1.) Marker (kDa)
2.) Whole Lysate (+ Ligand)
3.) Clarified Lysate (+)
4.) Flow Through (+)
5.) pH 7.5 (+) elution
6.) pH 7.0 (+) elution
7.) pH 6.5 (+) elution
8.) Whole Lysate (- Ligand)
9.) Clarified Lysate (-)
10.) Flow Through (-)
11.) pH 7.5 (-) elution
12.) pH 7.0 (-) elution
13.) pH 6.5 (-) elution
1    2     3     4    5    6    7    8     9   10   11   12  13  
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which is what caused the signal increase when running β-gal assays. Though this hasn't 
been proven directly, this is the best explanation for the phenomenon observed here.
The goal, however, was to develop an in-vitro colorimetric assay. As such, attempts were 
made to purify the protein and add ligands after purification so that the target protein 
could be purified in quantity which would make the assay much faster and presumably 
more sensitive since there would be fewer molecules affecting the assay after
purification. For the next experiment, MIβ-gal::ERβ was grown and expressed at 37°C 
and pH 7.0 for 3 hours in the absence of ligand. Ligand (estradiol) was then added and 
incubated for an additional 3 hours with a negative control sample (DMSO). Time points 
were then taken at 0.5, 1, 2, and 3 hours of incubation. Each data point was then run on a 
n SDS-PAGE protein gel and the results can be seen below in Figure 4.
Figure 4: SDS-PAGE gel of purified MIβ-gal::ERβ expressed at 37°C for 3 hours with no 
ligand and purified at pH 7.0 with ligand and no ligand added after purification.
1.) Marker (kDa)
2.) pH 7.0 (0.5h) + Ligand
3.) pH 7.0 (1h) + Ligand
4.) pH 7.0 (2h) + Ligand
5.) pH 7.0 (3h) + Ligand
6.) pH 7.0 (0.5h) DMSO
7.) pH 7.0 (1h) DMSO
8.) pH 7.0 (2h) DMSO
9.) pH 7.0 (3h) DMSO
116
66
45
35
25
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As seen in Figure 4, ligand additions after purification produced no change in cleavable 
products, again, because of the hypothesized improper folding of the ligand binding 
domain in the absence of a stabilizing molecule (ligand) during translation. β-gal assays 
were performed on each sample (data not shown), and the activity between ligand and 
DMSO samples was nearly identical, but the activity also decreased in both samples as 
the incubation time increased. 
Since in-vitro ligand additions appeared to have no effect on the protein of interest, the 
idea of using another stabilizer molecule that would bind to the receptor during 
translation but not cause cleavage was implemented into the experiments. The molecule 
of interest was an estrogen antagonist called raloxifene and historically, this molecule did 
not cause cleavage of the C-extein portion of the intein. Once raloxifene binded to the 
receptor weakly (higher dissociation constant), a tightly-binding agonist could potentially 
displace the antagonist in-vitro and cause cleavage and the desired activity increase. The 
next set of experiments consisted of expressing the MIβ-gal::ERβ protein in the presence 
of the antagonist raloxifene and in the presence of both raloxifene and estradiol (agonist) 
and then purifying each sample in an effort to determine binding affinity of  raloxifene 
and to see if any cleavage products would form. The SDS-PAGE results can be seen in 
Figure 5.
Figure 5: Purification of MIβ
(raloxifene) and antagonist + agonist (estradiol)
In Figure 5, it is clear that the sample expressed in both agonist and antagonist exhibits 
the same cleavage band around 88 kDa which is analagous to previous results involving 
expression of the target pro
the sample expressed in only the antagonist produces no cleavable products near the 88 
kDa marker as expected. However, from this experiment, it is impossible to tell if the 
raloxifene antagonist was binding to the target protein at all in either sample. It is 
possible that in the antagonist sample, the raloxifene was not binding at all which would 
still give the same result of no cleavage products on the SDS
combination sample, if the raloxifene antagonist wasn't binding, the same result of the 
cleavage band at 88 kDa in lane 9 would have been obtained. 
1      2       3     4      5       
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-gal::ERβ at 37°C at pH 7.5 expressed with antagonist 
tein in the presence of a tightly binding ligand. By contrast, 
-PAGE gel. In the 
1.) Marker 9kDa)
2.) WL Raloxifene (ant.)
3.) CL Raloxifene (ant.)
4.) FT Raloxifene (ant.)
5.) Purified protein (Ralox.)
6.) WL Ralox. + E2 (ant. + agon.)
7.) CL Ralox. + E2 (an
8.) FT Ralox. + E2 (ant. + agon.)
9.) Purified protein (Ralox. + E2)
All at pH 7.5
6       7      8     9
t. + agon.)
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As a result, another experiment was designed to investigate if the estrogen antagonist was 
binding. Here, the antagonist was still introduced during expression, but a variety of 
estrogen agonists with varying binding affinities were added in an effort to displace the 
raloxifene antagonist and cause a β-gal activity increase. The ligand agonists that were 
added after purification were diethylstilbestrol (DES), estradiol (E2), and bisphenol a 
(BPA) with binding affinities in that order (tight to weak). Figure 6 displays the results of 
the SDS-PAGE gel.
Figure 6: Purification of MIβ-gal::ERβ at 37°C at pH 7.5 expressed with antagonist 
(raloxifene) with a variety of agonists added after purification
Again, there were no cleavage bands visibile near the 88 kDa marker (thick red band). 
Possible explanations for this are that the raloxifene wasn't binding during expression so 
1.) WL Raloxifene (ant.)
2.) CL Raloxifene (ant.)
3.) FT Raloxifene (ant.)
4.) Purified protein (Ralox.)
5.) purified + DES
6.) purified + E2
7.) purified + BPA
8.) purified + DMSO
9.) Marker (kDa)
All at pH 7.5 incubated for 12 h 
overnight at RT
1       2      3     4       5      6     7     8        9
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that the ligand binding domain was still improperly folding or that the ligand binding 
domain was folding around the molecule but the active site was still getting buried upon 
release of the antagonist. It is very difficult to prove either hypothesis directly, but 
another experiment was designed which involved trying to displace the antagonist before 
purification after cell lysis. The rationale was that the purification process was dialyzing 
the stabilizing antagonist molecule out which was then causing the active site to become 
mis-folded or buried. 
For this experiment, the target protein MIβ-gal::ERβ was expressed at 37°C with 
estradiol (agonist, positive control), DMSO (negative control), and raloxifene (target 
sample of interest). Diethylstilbestrol (strongest agonist in the lab) was then added to 
each sample after cell lysis but before purification and incubated for 18 hours at 37°C, 
4°C, and room temperature. The DMSO sample was expected to have an improperly 
folded ligand-binding domain and hence no cleavage and the lowest activity. The E2 
sample was expected to exhibit cleavage and an activity increase as in the previous 
experiments. Finally, the raloxifene sample was expected to be displaced and have 
activity and cleavage products similar to that of the positive control (E2) sample. The 
results can be seen in Table 10.
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Table 10: β-gal activity assay results of MIβ-gal::ERβ expressed with E2, DMSO, and 
Raloxifene with DES agonist added to cell lysates.
Temperature/OD405 reading Expression Molecule
37C DMSO E2 Raloxifene
OD450 0.705 0.696 0.642
4C
OD450 1.048 0.972 0.847
RT
OD450 1.02 0.964 0.844
In Table 10, the activity was compared using the OD405 rather than the full Miller Units 
equation for convenience and because the OD405 was the governing value of the equation. 
Table 10 also shows a different trend as expected because the negative control (DMSO) 
has higher activity at all three measured temperatures than either the target sample or the 
positive control (E2). It was observed that there was significant protein aggregation at 
37°C  so the experiment was repeated at only room temperature. The results were 
expected to be the same with no discernible trend, but Table 11 and 12 show the new 
trend that was discovered.
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Table 11: β-gal activity assay results of MIβ-gal::ERβ expressed with E2, DMSO, and 
Raloxifene with DES agonist added to cell lysates at room temperature (suspensions)
Suspensions
Temperature/OD405 reading Expression Molecule
RT DMSO E2 Raloxifene
OD450 0.6 0.886 0.756
RT (duplicate)
OD450 0.76 0.966 0.913
Table 12: β-gal activity assay results of MIβ-gal::ERβ expressed with E2, DMSO, and 
Raloxifene with DES agonist added to cell lysates at room temperature (centrifuged)
Centrifuged
Temperature/OD405 reading Expression Molecule
RT DMSO E2 Raloxifene
OD450 0.366 0.52 0.552
RT (duplicate)
OD450 0.382 0.581 0.561
In Tables 11 and 12, the protein had aggregated slightly even at room temperature so the 
activity and cleavage products were analyzed for both the suspensions and centrifuged 
products of each sample. The trend was surprisingly close to what was expected with the 
negative control containing the lowest activity while the positive control and target 
sample contained higher activity. Upon purification of the clarified samples, the trend 
was still conserved, but there was no difference in cleavage products for any sample on 
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an SDS-PAGE gel (data not shown) so the difference in activity was rendered as noise. If 
the diethylstilbestrol ligand was displacing the raloxifene, it would be expected to cause 
cleavage for the activity increase, but this was not observed. It is possible that the protein 
was undergoing proteolysis and nonspecific degradation, but this has not been proven and 
the results from Table 11 and 12 are inconclusive. With the exhaustive work obtaining 
inconclusive data and with time quickly running out, the project was terminated at this 
point and no further work was completed on this project.
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Summary of Results
In-vivo additions of appropriate ligands produced noticeable changes in cleavage 
products consistent with intein C-extein cleavage along with increased β-gal activity in 
both the MIβ-gal::ERβ clone and the MIβ-gal::TRβ clone. The assay time was greatly 
minimized with this proposed platform from other platforms, but ligand specificity was 
lost and there was no apparent correlation with ligand-binding affinity and signal 
strength. Additions of ligand agonists in-vitro to the estrogen receptor (ERβ) protein both 
before and after purification also produced no signal. Several attempts were then made 
involving adding a weakly binding antagonist (raloxifene) to potentially get displaced 
with a tightly binding agonist to obtain the desired activity change. These attempts failed 
when expressing the protein of interest with the antagonist and trying to displace it both 
before and after purification. No meaningful data was obtained after the initial in-vivo 
ligand addition experiments and the project was terminated. 
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Conclusions
The work presented here was based primarily on the original phenotype growth biosensor 
platform developed by David Wood [1-5]. The new MIβ-gal::ERβ/TRβ clones were 
experimentally confirmed to contain the β-gal substitution for TS. The MIβ-
gal::ERβ/TRβ clones exhibited significantly increased β-gal activity when the appropriate 
ligand was added in-vivo during overday growth or expression and the protein also 
cleaved at what is presumed to be the C-extein which was observed on an SDS-PAGE 
gel. The mechanism of action is still unknown, but in-vivo ligand additions correlate very 
strongly with cleaved products. For the MIβ-gal::ERβ clone, however, no cleavage or 
difference in activity was observed when ligands were added to the lysate or to the 
purified product either with or without the antagonist added during expression. The 
results presented in the Thesis support both the hypothesis that the ligand-binding domain 
was misfolding along with the hypothesis that the intein cleavage reaction had something 
to do with the increase in β-gal activity that was observed. In-vitro activity increase or 
cleavage had never been observed with either the TS platform or the β-gal platform 
presented in this Thesis. Other attempts were made in the lab to translate the protein in-
vitro with the help of an in-vitro translation kit in an effort to help the ligand-binding 
domain fold properly outside of the cell so that ligand-induced cleavage could take place, 
but these attempts generated no meaningful data. As such, this project has answered some 
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important questions, but has ultimately failed to meet the goal of developing an in-vitro 
colorimetric ligand-binding affinity assay. The in-vivo work produced some good data, 
but this semi-functional assay platform has proven to be mostly analogous to other 
platforms both in this lab and in the field and there are no real added benefits.
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